

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(1)

John Teerlink, M.D.

Committee: Cardiovascular and Renal Drugs Advisory Committee

Meeting Date: April 18, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the agenda item concerning the discussion of Supplemental New Drug Application (NDA) 20-758/S-037, Avalide (irbesartan/HCTZ), sponsored by Bristol Myers Squibb and Sanofi-Synthelabo, a subsidiary of Sanofi-Aventis, for use in the treatment of hypertension in patients unlikely to achieve blood pressure goals on one drug, I am eligible to receive a waiver under 18 U.S.C. §208(b)(1).

| Type of Interest | Nature | Magnitude |
|--------------------------------------|---------------------------|---|
| Unrelated Steering Committee | Competing Firm | Less than \$10,001 per year. |
| Blinded Endpoint Reviewer | Sponsor | From \$10,001 to \$50,000 per year. |
| Stock in a Health Sector Mutual Fund | Health Sector Mutual Fund | Valued at between \$50,000 and \$100,000. |

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests, the waiver is not valid.

 /S/
Signature of SGE

 3/05/07
Date